Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma, Extranodal NK-T-Cell × Ifosfamide × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 9 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Ovarian Neoplasms 4 Lung Neoplasms 4 Leukemia 4 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Non-Hodgkin 3 Hodgkin Disease 3 Testicular Neoplasms 2 Relapsed Pediatric Solid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Lymphoma, T-Cell, Peripheral 2 Fallopian Tube Neoplasms 2 Central Nervous System Neoplasms 2 Burkitt Lymphoma 2 Breast Neoplasms 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Unresectable Sinonasal Tumors 1 Testicular Germ Cell Tumor 1 Teratoma 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Spinal Cord Neoplasms 1 Sinonasal Tumors 1 Seminoma 1

Interventions

pegaspargase 13 Dexamethasone 10 Gemcitabine 8 Etoposide 8 spartalizumab 5 Oxaliplatin 4 sintilimab 3 Methotrexate 3 Asparaginase 3 tislelizumab 2 camrelizumab 2 Radiotherapy 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Cyclophosphamide 2 Busulfan 2 Azacitidine 2 tofacitinib 1 pembrolizumab 1 fludarabine phosphate 1 apatinib 1 Thalidomide 1 Sensitivity and Specificity 1 Psychiatric Rehabilitation 1 Pharmacogenomic Testing 1 PC61 monoclonal antibody 1 Mycophenolic Acid 1 Melphalan 1 Ketamine 1 Ifosfamide 1 Gelox 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02544425 2020-10-22

VIDL+ASCT

Samsung Medical Center

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡